Development of Epstein-Barr Virus-related Primary Diffuse Large B-cell Lymphoma of the Central Nervous System in a Patient with Peripheral T-cell Lymphoma, Not Otherwise Specified after Mogamulizumab Treatment

Tanaka, Hiroaki; Aoki, Hirotaka; Sugita, Yoshiaki; Shimizu, Ryo; Kiko, Katsunari; Mochida, Hidetoshi; Suzuki, Yoshio

doi:10.2169/internalmedicine.8781-16

Cited by 6 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ecthyma gangrenosum can complicate MOG treatment of SS and is mostly related to the global immunosuppression induced by the disease itself, as CTCL tumoral lymphocytes present a mostly Th2 profile and produce TGF-beta [107]. Other infectious-related problems, such as EBV T-LPD involving the central nervous system (CNS), which develops in severely immunocompromised subjects [108][109][110], mostly with impaired T-cell immunity, have been reported in a patient with AITL with incomplete T-cell reconstitution who received conventional chemotherapy and MOG [111].…”

Section: Cutaneous Adverse Eventsmentioning

confidence: 99%

Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review

Fernández-Guarino,

Ortiz,

Gallardo

et al. 2024

IJMS

View full text Add to dashboard Cite

Mogamulizumab (MOG) is an antibody targeting the CCR4 receptor, authorized for relapsed or refractory peripheral T-cell (PTCL) and cutaneous T-cell lymphomas (CTCL). Its adoption in guidelines and endorsement by FDA and EMA established it as a systemic treatment, especially for advanced disease stages due to its comparatively lower toxicity. Clinical trials and real-world evidence have underscored its efficacy in advanced CTCLs, including mycosis fungoides and Sézary syndrome; PTCLs; and adult T-cell leukemia/lymphoma (ATLL), showcasing positive outcomes. Notably, the drug has demonstrated significant response rates, disease stability, and extended periods of progression-free survival, suggesting its applicability in cases with multiple treatment lines. Its safety profile is generally manageable, with adverse events (AEs) primarily related to the skin, infusion-related reactions, drug eruptions, autoimmune diseases, and skin disorders. The latter seem to appear as CCR4 can promote the skin-specific homing of lymphocytes, and MOG is directed against this receptor. While combination with immunostimulatory agents like interferon alpha and interleukin 12 has shown promising results, caution is urged when combining with PD1 inhibitors due to the heightened risk of immune-mediated AEs. The introduction of MOG as a systemic treatment implies a significant advancement in managing these diseases, supported by its favorable safety profile and complementary mechanisms.

show abstract

Section: Cutaneous Adverse Eventsmentioning

confidence: 99%

Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review

Fernández-Guarino,

Ortiz,

Gallardo

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Other reported severe adverse events associated with Mogamulizumab treatment include reactivation of hepatitis B virus (HBV) [ 172 , 173 , 174 ], occurrence of brain EBV-positive diffuse large cell B cell lymphoma (EBV + DLBCL) [ 175 , 176 ], and cytomegalovirus (CM) infections [ 174 , 177 ]. These events are all known to be associated with immunocompromised hosts.…”

Section: Adverse Events By Mogamulizumabmentioning

confidence: 99%

CCR4 as a Therapeutic Target for Cancer Immunotherapy

Yoshie

2021

Cancers

View full text Add to dashboard Cite

CCR4 is a chemokine receptor mainly expressed by T cells. It is the receptor for two CC chemokine ligands, CCL17 and CCL22. Originally, the expression of CCR4 was described as highly selective for helper T type 2 (Th2) cells. Later, its expression was extended to other T cell subsets such as regulatory T (Treg) cells and Th17 cells. CCR4 has long been regarded as a potential therapeutic target for allergic diseases such as atopic dermatitis and bronchial asthma. Furthermore, the findings showing that CCR4 is strongly expressed by T cell malignancies such as adult T cell leukemia/lymphoma (ATLL) and cutaneous T cell lymphomas (CTCLs) have led to the development and clinical application of the fully humanized and glyco-engineered monoclonal anti-CCR4 Mogamulizumab in refractory/relapsed ATLL and CTCLs with remarkable successes. However, Mogamulizumab often induces severe adverse events in the skin possibly because of its efficient depletion of Treg cells. In particular, treatment with Mogamulizumab prior to allogenic hematopoietic stem cell transplantation (allo-HSCT), the only curative option of these T cell malignancies, often leads to severe glucocorticoid-refractory graft-versus-host diseases. The efficient depletion of Treg cells by Mogamulizumab has also led to its clinical trials in advanced solid tumors singly or in combination with immune checkpoint inhibitors. The main focus of this review is CCR4; its expression on normal and malignant T cells and its significance as a therapeutic target in cancer immunotherapy.

show abstract